Hugel highlights global vision for K-aesthetics
- K-aesthetics is poised to shape the future of global medical beauty, says Hugel's President and Global CEO
- Strom emphasizes aesthetics' role in boosting confidence and quality of life
Amid growing global interest in the Korean aesthetics industry, Strom delivered a presentation titled "K-Aesthetics on the Global Stage: Leadership, Innovation, and the Next Chapter." She participated as the conference's sole speaker representing the medical aesthetics sector and as one of the featured female global business leaders.
"K-aesthetics is expanding its global influence through consumer-centric services and sophisticated treatment approaches," Strom said. "Going forward, it is expected to become a key force shaping the future of the global medical aesthetics industry. K-beauty has already become a major global trend, and K-aesthetics represents the next evolution of that movement. By combining in-office medical aesthetic procedures with multiple treatment modalities, K-aesthetics delivers natural, skin-first outcomes that increasingly resonate with consumers worldwide."
She also noted that consumer attitudes toward aesthetics have evolved since the pandemic. "Consumers are increasingly seeking ways to enhance their confidence and overall well-being," she said. "Aesthetics today is no longer just about appearance — it is increasingly connected to better quality of life and self-esteem. Our Phase III clinical trial on Letybo, demonstrated that botulinum toxin treatment can help alleviate the psychological burden associated with glabellar lines[1] while improving quality of life, a younger perceived age, and satisfaction with outcomes."
Hugel's global potential was a key reason she joined the company. "Hugel is the only Korean company to have entered all three major botulinum toxin markets — the
Strom added that Hugel is not resting on its position as
"
[1] Cox, S. E., et al., LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials, Dermatologic Surgery Vol.50, No.6 (2024), pp.535-541. DOI:10.1097/DSS.0000000000004152. |
About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums.
Over the past 20 years, the company has built a presence in approximately 70 countries and operates nine global subsidiaries across the US,
Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/hugel-highlights-global-vision-for-k-aesthetics-302779787.html
SOURCE Hugel
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PureHealth Research Peptide Supplements Expand with New Morikol® Tripeptide Formula for Faster Cellular Absorption
- Venture Insights Opens Its Diagnostic to Saudi Founders at No Cost and Has a Named Expert Sign Every Playbook
- Building Against the Attention Economy: Mohammed Abdul Kamran Brings His Privacy-First Vision to Faith Technology
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share